Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—The Phase III MECCA Trial

Mené en Chine sur 263 patientes atteintes d'un cancer du sein métastatique HR+ HER2- (durée médiane de suivi : 50,7 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout d'un traitement métronomique par capécitabine à un inhibiteur d'aromatase

Résumé en anglais

Purpose : The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.

Methods : Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for